Data protection Impressum

Neuroscience

Geneva-based biotech Stalicla secures funding to advance precision medicine programs for autism and substance use disorders.

Addex Therapeutics leads CHF 2 million investment in Stalicla

14 July 2025

Superlab Suisse will open a new laboratory at Campus Biotech in Geneva in January 2026, strengthening the region’s innovation infrastructure for life sciences start-ups.

Superlab expands to Geneva with new lab at Campus Biotech

25 June 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (March 2025)

26 March 2025

Geneva has unveiled its new Innovation Master Plan 2025-2027 (“Plan Directeur de l’Innovation 2025-2027” in French), designed to consolidate the canton’s position as a leading international innovation hub. Backed by CHF 11 million in public investment, the strategy focuses on infrastructure enhancement, targeted financing, and fostering entrepreneurship to bolster Geneva’s economic strength.

Geneva strengthens its innovation ecosystem with a strategic development plan

10 March 2025

Geneva-based Neurosoft Bioelectronics has set a new benchmark in neurotechnology with its high-resolution, stretchable brain interface for epilepsy monitoring. The EPFL spin-off successfully tested its device on two human patients, paving the way for broader clinical applications.

Neurosoft Bioelectronics advances brain interface technology for epilepsy and tinnitus

5 March 2025

The University Hospitals of Geneva (HUG), the Department of Health and Mobilities (DSM) of the Canton of Geneva, and the Wyss Center are joining forces to establish Switzerland’s first artificial intelligence health hub at Campus Biotech, set to open in the second half of 2025.

An artificial intelligence health hub is set to open at Campus Biotech

17 February 2025

Geneva-based BrainScape Medical, a newly incorporated company specializing in neuromonitoring and neurostimulation technologies, has announced several milestones, including new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.

BrainScape Medical makes strides in long-term brain monitoring

21 January 2025

ONWARD Medical has achieved a significant milestone with FDA de novo classification and market authorization for its non-invasive ARC-EX System, the first technology approved to enhance hand strength and sensation after chronic spinal cord injury.

ONWARD Medical receives FDA authorization for its spinal cord stimulation system

6 January 2025

ONWARD Medical has raised EUR 50 million through an upsized private placement, establishing a strategic partnership with Ottobock. The funds will drive ONWARD’s research and commercialization of spinal cord therapies, with plans for collaboration with Ottobock on future innovations.

ONWARD Medical raises EUR 50 million and welcomes a new strategic partner

28 October 2024

ONWARD Medical has secured a USD 1.1 million grant from the Christopher & Dana Reeve Foundation to further develop its ARC-BCI system, which aims to restore thought-controlled movement to people with spinal cord injuries.

ONWARD Medical awarded USD 1.1 million by the Christopher & Dana Reeve Foundation

17 September 2024

1 2